Michael Dao

LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial

Rohit Loomba, Joel Neutel, Rizwana Mohseni et al. · Journal of Hepatology · 2019 · 85 citations

Pharmacy, Pharmacology, Pharmacotherapy +12

Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization

Tracy Y. Wang, Abdus S. Wahed, Alison Morris et al. · Annals of Internal Medicine · 2023 · 36 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension

Akshay S. Desai, Adam Karns, Jolita Badarienė et al. · JAMA · 2025 · 27 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A First‐in‐Patient, Multicenter, Double‐Blind, 2‐Arm, Placebo‐Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP‐499, in Chronic Kidney Disease

LuAnn Sabounjian, Philip B. Graham, Lijun Wu et al. · Clinical Pharmacology in Drug Development · 2015 · 26 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16

Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia

Dariush Mozaffarian, Kevin C. Maki, Harold Bays et al. · JAMA Network Open · 2022 · 24 citations · Full text

Life Sciences, Nutrition, Nutritional Sciences +17